Azacytidine Plus FLAG for Relapsed or Refractory AML
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to
fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid
leukemia.